Persistent elevation of plasma thrombopoietin levels after treatment in severe aplastic anemia
Open Access
- 1 February 2018
- journal article
- research article
- Published by Elsevier in Experimental Hematology
- Vol. 58, 39-43
Abstract
No abstract availableKeywords
Funding Information
- National Heart, Lung, and Blood Institute
This publication has 18 references indexed in Scilit:
- Eltrombopag restores trilineage hematopoiesis in refractory severe aplastic anemia that can be sustained on discontinuation of drugBlood, 2014
- Eltrombopag and Improved Hematopoiesis in Refractory Aplastic AnemiaNew England Journal of Medicine, 2012
- Horse versus Rabbit Antithymocyte Globulin in Acquired Aplastic AnemiaNew England Journal of Medicine, 2011
- Cytokine signature profiles in acquired aplastic anemia and myelodysplastic syndromesHaematologica, 2010
- Hematopoietic growth factors in aplastic anemia patients treated with immunosuppressive therapy-systematic review and meta-analysisHaematologica, 2009
- Preclinical Activity of Eltrombopag (SB-497115), an Oral, Nonpeptide Thrombopoietin Receptor AgonistStem Cells, 2009
- Critical Role of Thrombopoietin in Maintaining Adult Quiescent Hematopoietic Stem CellsCell Stem Cell, 2007
- Posttransplant Thrombopoiesis Predicts Survival in Patients Undergoing Autologous Hematopoietic Progenitor Cell TransplantationTransplantation and Cellular Therapy, 2007
- Hematopoietic growth factors in the pathogenesis and for the treatment of aplastic anemiaSeminars in Hematology, 2000
- CRITERIA FOR SEVERE APLASTIC ANAEMIAThe Lancet, 1988